Digital Twins in Biotech, Bioprocessing & Biosimilar Development: from concept to implementation
A digital twin isn't a dashboard bolted onto your bioreactor. It is a live, running model of the entire process chain, from raw materials to final product. Here's what that actually takes to build, and where it pays for itself first.
A bioprocess digital twin is a model of your full process chain: every unit operation predicting how it affects every other one, updated as real data comes in. Not a dashboard. Not a spreadsheet. A model you can ask, "what happens if I change this?" and trust the answer.
Three places a twin earns its keep
Process Development
Organizes platform knowledge and points to the highest-value next experiment instead of running every combination.
Process Validation
Sets data-driven NORs and acceptance criteria, and can justify fewer PPQ batches.
GMP Manufacturing
Flags out-of-specification risk before it happens and speeds up root-cause investigation.
A published Boehringer Ingelheim, Versatis and Korber case study (Bioengineering 2017, 4(4):86) described a twin that justified fewer PPQ batches and set data-driven NORs and alert limits, aligned with FDA's QbD initiative.
The real challenges teams actually hit
Most digital twin write-ups stop at benefits. In practice, the work is shaped by the data, instrumentation, validation burden, and people available to operate the model.
Fragmented Data
Batch records sit in paper or PDF, historian data is siloed by system, and there is no single asset-centric store to model from.
Biology Resists Modeling
Cell metabolism is nonlinear and shifts batch to batch, so pure ODE/PDE mechanistic models rarely capture it alone.
Regulatory Trust
A model has to be defensible enough to support reduced PPQ batches or tighter NORs. That is a validation burden, not just a modeling exercise.
Missing Instrumentation
Legacy skids and bioreactors without PAT sensors cannot feed a twin in real time. The hardware gap can come before the modeling gap.
Skills Gap
It needs bioprocess SMEs and data scientists working together. Most teams have one or the other, rarely both.
Slow Payback
A validated twin takes months to build and prove out, which makes a narrow first use case essential under quarterly pressure.
Five practical steps
Audit your data before your models
Map what is already digitized versus what is stuck in paper batch records or a disconnected historian. This determines what is buildable, not the modeling approach.
Pick one unit operation, not the whole train
Choose the step you understand best and where a bad prediction is cheapest to catch, such as the bioreactor rather than the full purification chain.
Go hybrid, not fully mechanistic
Pair the mechanistic model you can defend with statistical or Bayesian layers to cover what biology will not fit cleanly into equations.
Validate against historical batches first
Backtest the model on runs with known outcomes before trusting it on a live batch or using it to justify a validation decision.
Expand only after the first twin proves value
Use the first success to justify instrumenting the next unit operation and connecting it into the same environment.
This is already a product, not just a concept
Simulate the right experiments before the lab does.
Novasign's platform segments a process into stages such as growth and production, runs thousands of simulated parameter combinations in parallel, and lets a scientist change a parameter and immediately see the expected impact on titer, yield, or cost with confidence intervals.
Why this matters even more for biosimilars
Biosimilar programs carry an extra constraint: every process decision has to be defended against a reference product's quality profile. A platform-linked twin built once can be reused across programs to tighten acceptance criteria and support a leaner PPQ campaign. The twin does not care whether the molecule is novel or a biosimilar, only whether the platform knowledge behind it has been captured in a form the model can use.
From data audit to a working first twin
Graphtal supports biopharma, CDMO, and biosimilar teams through digital twin readiness: auditing data, selecting the right first unit operation, building the hybrid model, and validating it against historical batches before it touches a live decision.
Tell Us About Your Project
Our team of experienced professionals at Graphtal is ready to transform your project from idea to reality, ensuring alignment with your organisation goals through advanced data analytics and predictive modelling.
Let's simplify your work